Cargando…
The Potential Equivalents of TET2 Mutations
SIMPLE SUMMARY: In acute myeloid leukemia (AML) TET2 mutations have been observed to be mutually exclusive with IDH1, IDH2, and WT1 mutations, all of them showing a similar impact on the transcription profile. Because of this, it is possible that TET2/IDH1/2/WT1 mutated AML could be considered as ha...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036366/ https://www.ncbi.nlm.nih.gov/pubmed/33805247 http://dx.doi.org/10.3390/cancers13071499 |
_version_ | 1783676893235511296 |
---|---|
author | Pasca, Sergiu Jurj, Ancuta Zdrenghea, Mihnea Tomuleasa, Ciprian |
author_facet | Pasca, Sergiu Jurj, Ancuta Zdrenghea, Mihnea Tomuleasa, Ciprian |
author_sort | Pasca, Sergiu |
collection | PubMed |
description | SIMPLE SUMMARY: In acute myeloid leukemia (AML) TET2 mutations have been observed to be mutually exclusive with IDH1, IDH2, and WT1 mutations, all of them showing a similar impact on the transcription profile. Because of this, it is possible that TET2/IDH1/2/WT1 mutated AML could be considered as having similar characteristics between each other. Nonetheless, other genes also interact with TET2 and influence its activity. Because of this, it is possible that other signatures exist that would mimic the effect of TET2 mutations. Thus, in this review, we searched the literature for the genes that were observed to interact with TET2 and classified them in the following manner: transcription alteration, miRs, direct interaction, posttranslational changes, and substrate reduction. ABSTRACT: TET2 is a dioxygenase dependent on Fe(2+) and α-ketoglutarate which oxidizes 5-methylcytosine (5meC) to 5-hydroxymethylcytosine (5hmeC). TET proteins successively oxidize 5mC to yield 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). Among these oxidized methylcytosines, 5fC and 5caC are directly excised by thymine DNA glycosylase (TDG) and ultimately replaced with unmethylated cytosine. Mutations in TET2 have been shown to lead to a hypermethylated state of the genome and to be responsible for the initiation of the oncogenetic process, especially in myeloid and lymphoid malignancies. Nonetheless, this was also shown to be the case in other cancers. In AML, TET2 mutations have been observed to be mutually exclusive with IDH1, IDH2, and WT1 mutations, all of them showing a similar impact on the transcription profile of the affected cell. Because of this, it is possible that TET2/IDH1/2/WT1 mutated AML could be considered as having similar characteristics between each other. Nonetheless, other genes also interact with TET2 and influence its effect, thus making it possible that other signatures exist that would mimic the effect of TET2 mutations. Thus, in this review, we searched the literature for the genes that were observed to interact with TET2 and classified them in the following manner: transcription alteration, miRs, direct interaction, posttranslational changes, and substrate reduction. What we propose in the present review is the potential extension of the TET2/IDH1/2/WT1 entity with the addition of certain expression signatures that would be able to induce a similar phenotype with that induced by TET2 mutations. Nonetheless, we recommend that this approach be taken on a disease by disease basis. |
format | Online Article Text |
id | pubmed-8036366 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80363662021-04-12 The Potential Equivalents of TET2 Mutations Pasca, Sergiu Jurj, Ancuta Zdrenghea, Mihnea Tomuleasa, Ciprian Cancers (Basel) Review SIMPLE SUMMARY: In acute myeloid leukemia (AML) TET2 mutations have been observed to be mutually exclusive with IDH1, IDH2, and WT1 mutations, all of them showing a similar impact on the transcription profile. Because of this, it is possible that TET2/IDH1/2/WT1 mutated AML could be considered as having similar characteristics between each other. Nonetheless, other genes also interact with TET2 and influence its activity. Because of this, it is possible that other signatures exist that would mimic the effect of TET2 mutations. Thus, in this review, we searched the literature for the genes that were observed to interact with TET2 and classified them in the following manner: transcription alteration, miRs, direct interaction, posttranslational changes, and substrate reduction. ABSTRACT: TET2 is a dioxygenase dependent on Fe(2+) and α-ketoglutarate which oxidizes 5-methylcytosine (5meC) to 5-hydroxymethylcytosine (5hmeC). TET proteins successively oxidize 5mC to yield 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). Among these oxidized methylcytosines, 5fC and 5caC are directly excised by thymine DNA glycosylase (TDG) and ultimately replaced with unmethylated cytosine. Mutations in TET2 have been shown to lead to a hypermethylated state of the genome and to be responsible for the initiation of the oncogenetic process, especially in myeloid and lymphoid malignancies. Nonetheless, this was also shown to be the case in other cancers. In AML, TET2 mutations have been observed to be mutually exclusive with IDH1, IDH2, and WT1 mutations, all of them showing a similar impact on the transcription profile of the affected cell. Because of this, it is possible that TET2/IDH1/2/WT1 mutated AML could be considered as having similar characteristics between each other. Nonetheless, other genes also interact with TET2 and influence its effect, thus making it possible that other signatures exist that would mimic the effect of TET2 mutations. Thus, in this review, we searched the literature for the genes that were observed to interact with TET2 and classified them in the following manner: transcription alteration, miRs, direct interaction, posttranslational changes, and substrate reduction. What we propose in the present review is the potential extension of the TET2/IDH1/2/WT1 entity with the addition of certain expression signatures that would be able to induce a similar phenotype with that induced by TET2 mutations. Nonetheless, we recommend that this approach be taken on a disease by disease basis. MDPI 2021-03-24 /pmc/articles/PMC8036366/ /pubmed/33805247 http://dx.doi.org/10.3390/cancers13071499 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Review Pasca, Sergiu Jurj, Ancuta Zdrenghea, Mihnea Tomuleasa, Ciprian The Potential Equivalents of TET2 Mutations |
title | The Potential Equivalents of TET2 Mutations |
title_full | The Potential Equivalents of TET2 Mutations |
title_fullStr | The Potential Equivalents of TET2 Mutations |
title_full_unstemmed | The Potential Equivalents of TET2 Mutations |
title_short | The Potential Equivalents of TET2 Mutations |
title_sort | potential equivalents of tet2 mutations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036366/ https://www.ncbi.nlm.nih.gov/pubmed/33805247 http://dx.doi.org/10.3390/cancers13071499 |
work_keys_str_mv | AT pascasergiu thepotentialequivalentsoftet2mutations AT jurjancuta thepotentialequivalentsoftet2mutations AT zdrengheamihnea thepotentialequivalentsoftet2mutations AT tomuleasaciprian thepotentialequivalentsoftet2mutations AT pascasergiu potentialequivalentsoftet2mutations AT jurjancuta potentialequivalentsoftet2mutations AT zdrengheamihnea potentialequivalentsoftet2mutations AT tomuleasaciprian potentialequivalentsoftet2mutations |